[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3200591T3 - Centrale hukommelses-t-celler til adoptiv t-celleterapi - Google Patents

Centrale hukommelses-t-celler til adoptiv t-celleterapi Download PDF

Info

Publication number
DK3200591T3
DK3200591T3 DK15842405.1T DK15842405T DK3200591T3 DK 3200591 T3 DK3200591 T3 DK 3200591T3 DK 15842405 T DK15842405 T DK 15842405T DK 3200591 T3 DK3200591 T3 DK 3200591T3
Authority
DK
Denmark
Prior art keywords
adoptive
cells
cell therapy
central memory
memory
Prior art date
Application number
DK15842405.1T
Other languages
English (en)
Inventor
Christine E Brown
Stephen J Forman
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3200591(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of DK3200591T3 publication Critical patent/DK3200591T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
DK15842405.1T 2014-09-19 2015-09-21 Centrale hukommelses-t-celler til adoptiv t-celleterapi DK3200591T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462053068P 2014-09-19 2014-09-19
PCT/US2015/051280 WO2016044853A1 (en) 2014-09-19 2015-09-21 Central memory t cells for adoptive t cell therapy

Publications (1)

Publication Number Publication Date
DK3200591T3 true DK3200591T3 (da) 2021-06-21

Family

ID=55533940

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15842405.1T DK3200591T3 (da) 2014-09-19 2015-09-21 Centrale hukommelses-t-celler til adoptiv t-celleterapi

Country Status (15)

Country Link
US (3) US9914909B2 (da)
EP (4) EP3194433B1 (da)
JP (7) JP6657195B2 (da)
KR (3) KR102683584B1 (da)
CN (4) CN107002084B (da)
AU (4) AU2015317351B2 (da)
BR (3) BR112017005631A2 (da)
CA (2) CA2961654A1 (da)
DK (1) DK3200591T3 (da)
ES (2) ES2738705T3 (da)
HK (1) HK1247046A1 (da)
IL (6) IL292650B2 (da)
MX (4) MX2017003596A (da)
RU (2) RU2749922C2 (da)
WO (2) WO2016044811A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3194433B1 (en) 2014-09-19 2019-05-22 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13r 2
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
WO2017015490A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
JP6751493B2 (ja) * 2015-08-05 2020-09-09 セルレブメド インコーポレーテッド キメラ抗原受容体及びキメラ抗原受容体が発現されたｔ細胞
CR20180461A (es) 2016-04-01 2019-03-05 Kite Pharma Inc Receptores de antígenos quiméricos y células t y métodos de uso
PE20211418A1 (es) 2016-04-01 2021-08-02 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
CR20180462A (es) * 2016-04-01 2019-04-01 Kite Pharma Inc Moleculas de unión a bcma y metodos de uso de las mismas
US20190183931A1 (en) * 2016-04-01 2019-06-20 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
JP2019527537A (ja) * 2016-06-07 2019-10-03 マックス−デルブリュック−セントルム フュール モレキュラー メディツィン イン デア ヘルムホルツ−ゲマインシャフト キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞
JP2019517267A (ja) * 2016-06-08 2019-06-24 イントレキソン コーポレーション Ｃｄ３３特異的キメラ抗原受容体
US11242376B2 (en) 2016-08-02 2022-02-08 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3512531A4 (en) * 2016-09-16 2020-03-11 Baylor College of Medicine VIRUS-SPECIFIC T-CELL ACTIVATION AND EXPANSION PLATFORM
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
US20200078401A1 (en) * 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
WO2018156711A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
KR102333377B1 (ko) * 2017-03-27 2021-11-30 노일 이뮨 바이오테크 가부시키가이샤 키메라 항원 수용체
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
WO2019033030A1 (en) * 2017-08-11 2019-02-14 City Of Hope ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF
WO2019087151A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
TW201940182A (zh) 2018-01-22 2019-10-16 美商安德賽特公司 Car t 細胞之使用方法
WO2019156795A1 (en) * 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
US20210038646A1 (en) * 2018-02-12 2021-02-11 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
SG11202008795SA (en) * 2018-03-14 2020-10-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
WO2019178085A1 (en) * 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
JP2021524248A (ja) * 2018-05-21 2021-09-13 バイオセプター・（ユーケー）・リミテッド 修飾されたリンカードメインを有するキメラ抗原受容体およびその使用
CN112533943B (zh) * 2018-06-01 2024-03-05 利兰斯坦福初级大学董事会 Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
US20210395329A1 (en) 2018-06-29 2021-12-23 City Of Hope Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
KR20210043622A (ko) * 2018-08-10 2021-04-21 주식회사 유틸렉스 암항원 특이적 세포독성 t세포
WO2020191336A1 (en) 2019-03-21 2020-09-24 Yamaguchi, Yukiko Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
EP4084808A1 (en) 2019-12-30 2022-11-09 City of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230374085A1 (en) * 2020-03-11 2023-11-23 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
CN115515971A (zh) * 2020-03-12 2022-12-23 希望之城公司 治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞
CA3184784A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN116963759A (zh) * 2020-09-10 2023-10-27 野马生物股份有限公司 包含靶向癌症的car-t细胞的组合疗法及使用其治疗癌症的方法
WO2022109498A1 (en) 2020-11-23 2022-05-27 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
JP2024510508A (ja) * 2021-03-18 2024-03-07 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー ＩＬ１３Ｒα２を標的とするＤＮＡコード化二重特異性抗体と癌治療における使用方法
WO2022212525A2 (en) 2021-03-30 2022-10-06 City Of Hope Car t cell therapy and ifn gamma
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096749T3 (es) 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1996025953A1 (en) * 1995-02-24 1996-08-29 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
EP1591128A1 (en) 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US11278594B2 (en) * 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ATE373904T1 (de) 2003-07-24 2007-10-15 Matsushita Electric Ind Co Ltd Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) * 2004-09-07 2006-03-09 Linde Ag Verfahren zur Synthese von Zirkoniumcarboxylaten
HUE030210T2 (en) 2004-11-24 2017-04-28 Hutchinson Fred Cancer Res Methods for using IL-21 to identify adoptive immunotherapy and tumor antigens
EP1963551A4 (en) 2005-12-21 2009-07-29 Univ Montreal T MEMORY LYMPHOCYTE MARKERS AND USES THEREOF
DE602006017435D1 (de) * 2005-12-21 2010-11-18 Sentoclone Ab Verfahren zur expansion tumorreaktiver t-lymphozyten zur immuntherapie von patienten mit krebs
WO2008095141A2 (en) 2007-01-31 2008-08-07 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
JP5592792B2 (ja) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
EP4032552B1 (en) * 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MX2012007318A (es) * 2009-12-22 2012-07-20 Novartis Ag Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
GB2481983A (en) * 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
EP2606124A1 (en) * 2010-08-18 2013-06-26 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
MA34813B1 (fr) * 2010-12-09 2014-01-02 Univ Pennsylvania Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
BR112013024395B1 (pt) * 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
EP2532740A1 (en) * 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
AU2013221672B2 (en) * 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US10780118B2 (en) * 2012-08-20 2020-09-22 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
AU2014376328A1 (en) * 2014-01-13 2016-07-21 Christine E. BROWN Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
EP3194433B1 (en) † 2014-09-19 2019-05-22 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13r 2

Also Published As

Publication number Publication date
AU2020203651A1 (en) 2020-06-25
MX2017003557A (es) 2017-10-12
MX2021012720A (es) 2022-01-06
RU2017111298A (ru) 2018-10-19
EP3200591B2 (en) 2024-09-25
HK1247046A1 (zh) 2018-09-21
ES2876235T3 (es) 2021-11-12
EP3194433B1 (en) 2019-05-22
IL308324A (en) 2024-01-01
EP3587446A1 (en) 2020-01-01
CN107002084B (zh) 2021-09-10
JP2020156494A (ja) 2020-10-01
IL292828A (en) 2022-07-01
JP2022017333A (ja) 2022-01-25
CA2961654A1 (en) 2016-03-24
WO2016044811A1 (en) 2016-03-24
IL251188B (en) 2022-07-01
JP6657195B2 (ja) 2020-03-04
US10676717B2 (en) 2020-06-09
RU2749922C2 (ru) 2021-06-21
BR112017005630A2 (pt) 2018-06-26
EP3916084A1 (en) 2021-12-01
KR20230169455A (ko) 2023-12-15
AU2015317351B2 (en) 2020-07-02
ES2738705T3 (es) 2020-01-24
AU2015317351A1 (en) 2017-04-06
EP3200591B1 (en) 2021-03-31
CN107404881A (zh) 2017-11-28
AU2024201326A1 (en) 2024-04-11
WO2016044853A8 (en) 2017-04-06
IL292650A (en) 2022-07-01
US9914909B2 (en) 2018-03-13
IL251196A0 (en) 2017-05-29
JP2017534262A (ja) 2017-11-24
IL292650B1 (en) 2023-12-01
KR102683584B1 (ko) 2024-07-10
CN107002084A (zh) 2017-08-01
RU2763523C2 (ru) 2021-12-30
IL280576B (en) 2022-06-01
EP3194433A1 (en) 2017-07-26
JP6986190B2 (ja) 2021-12-22
MX2021006400A (es) 2021-07-15
KR20170054509A (ko) 2017-05-17
BR112017005631A2 (pt) 2018-06-26
IL251188A0 (en) 2017-05-29
EP3200591A1 (en) 2017-08-09
BR112017005630B1 (pt) 2023-12-12
US20200318069A1 (en) 2020-10-08
EP3200591A4 (en) 2018-04-04
AU2021277651A1 (en) 2021-12-23
WO2016044853A1 (en) 2016-03-24
JP7216045B2 (ja) 2023-01-31
JP2020100626A (ja) 2020-07-02
JP2023014100A (ja) 2023-01-26
JP6711819B2 (ja) 2020-06-17
MX2017003596A (es) 2017-10-20
JP2017529081A (ja) 2017-10-05
CA2961676A1 (en) 2016-03-24
RU2017111300A3 (da) 2019-09-04
CN107404881B (zh) 2021-07-09
US20160340649A1 (en) 2016-11-24
JP2023052506A (ja) 2023-04-11
KR102610715B1 (ko) 2023-12-08
US20180265844A1 (en) 2018-09-20
CN113789336A (zh) 2021-12-14
CN113637640A (zh) 2021-11-12
RU2017111298A3 (da) 2019-03-13
JP7171871B2 (ja) 2022-11-15
NZ730208A (en) 2024-03-22
RU2017111300A (ru) 2018-10-19
BR122024000360A2 (pt) 2024-02-27
IL280576A (en) 2021-03-25
IL292650B2 (en) 2024-04-01
KR20170057351A (ko) 2017-05-24
IL251196B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
DK3200591T3 (da) Centrale hukommelses-t-celler til adoptiv t-celleterapi
GB2527282B (en) Support device
GB2545577B (en) Support system and structure supported thereby
DK2918828T3 (da) Kabelunderstøtningskonstruktion
DK3125898T3 (da) Farmakofor til trail-induktion
FR3030155B1 (fr) Multiplexeur analogique
ZA201503021B (en) Support arrangement
DK3098580T3 (da) Kombinationsvægtindretning
UA31197S (uk) Таблетка
GB201412079D0 (en) Support base
EP3202287A4 (en) Support device
DK3215118T3 (da) Lægemiddelanordningsenhed indeholdende quinagolid
PT3182940T (pt) Estrutura de apoio
GB2526401B (en) Packing support
GB201403767D0 (en) Support structure for radial application
DK3171140T3 (da) Kombinationsvægtindretning
GB201404263D0 (en) Support device
DE112015000374A5 (de) Trägereinrichtung
TWM490109U (en) Six-portion turntable structure
GB2523099B (en) Support Structure
GB2526701B (en) Watersport hiking support system
GB201414943D0 (en) Support device
GB201404204D0 (en) Support device
GB201416150D0 (en) Support structure
ZA201404575B (en) Support structure